PROPHYLACTIC PORTAL INFUSION CHEMOTHERAPY AS ADJUVANT THERAPY FOR THE PREVENTION OF METACHRONOUS LIVER METASTASIS IN COLORECTAL-CANCER

被引：7
作者：
KIMURA, O
KURAYOSHI, K
HOSHINO, K
SUGEZAWA, A
MAKINO, M
KAIBARA, N
机构：
[1] First Department of Surgery, Tottori University School of Medicine, Yonago, 683
来源：
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 03期
关键词：
LIVER METASTASIS; PORTAL INFUSION CHEMOTHERAPY; COLORECTAL CANCER; DNA INDEX; DNA PLOIDY;
D O I：
10.1007/BF00311529
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The DNA ploidy and DNA indices (DI) of 414 patients with colorectal cancer were analyzed, and the incidence of patients with metachronous liver metastasis was found to be significantly higher in those with aneuploid tumors and a DI above 1.5 than in those with aneuploid tumors and a DI below 1.4, or in those with diploid tumors and a DI equal to 1.0, Next, to confirm the effectiveness of administering prophylactic portal infusion chemotherapy (PPIC) as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer, a randomized controlled trial of PPIC was performed on 110 consecutive patients with primary colorectal cancer who had undergone curative resection. Although the incidence of patients with metachronous liver metastasis in the two study groups was not significantly different at 3.3% in the PPIC group and 10.3% in the control group, the incidence in the patients with aneuploidy and a DI above 1.5 was significantly lower in the PPIC group than in the control group, These findings suggest that colorectal cancer with aneuploidy and a DI above 1.5 may have a strong tendency to metastasize to the liver, and that prophylactic portal infusion chemotherapy may be effective for preventing metachronous liver metastasis in such patients.
引用
收藏
页码：211 / 216
页数：6
相关论文
共 16 条
  • [1] Taylor I., Machin D., Mullee M., Trotter G., Cooke T., West C., A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer, Br J Surg, 72, pp. 359-363, (1985)
  • [2] Cedermark B.J., Schultz S.S., Bakshi S., Parthasaranthy K.L., Mittelman A., Evans T.J., Value of liver scan in the followup study of patients with adenocarcinoma of the colon and rectum, Surg Gynecol Obstet, 144, pp. 745-748, (1977)
  • [3] Fisher E.R., Turnbull R.B., The cytological demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal cancer, Surg Gynecol Obstet, 100, pp. 102-106, (1955)
  • [4] Kimitsuki H., Experimental evaluation of chemotherapy in murine liver metastasis of colon cancer — antitumor effect of 5-Fu administered via the portal vein, Nippon Daicho Komon Byo Kaishi (J Jpn Soc Coloproctol), 45, pp. 259-265, (1992)
  • [5] Beart R.W., Moertel C.G., Wieand H.S., Leigh J.E., Windschitl H.E., van Heerden J.A., Fitzgibbons R.J., Wolff B.G., Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion, Arch Surg, 125, pp. 897-901, (1990)
  • [6] Wereldsma J.C.J., Bruggink E.D.M., Meijer W.S., Roukema J.A., van Putten W.L.J., Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control, Cancer, 65, pp. 425-432, (1990)
  • [7] Kokal W., Sheibani K., Tertz J., Harada R., Tumor DNA content in the prognosis of colorectal carcinoma, JAMA, 255, pp. 3123-3127, (1986)
  • [8] Kimura O., Kijima T., Moriwaki S., Hoshino K., Yonekawa M., Sugezawa A., Kaibara N., DNA index as a significant indicator of lymph node metastasis and local recurrence of rectal cancer, Dis Colon Rectum, 35, pp. 1130-1134, (1992)
  • [9] Kimura O., Kaibara N., Makino M., Nishidoi H., DNA ploidy in gastric cancer with metastasis to the liver, J Surg Oncol, 44, pp. 69-72, (1990)
  • [10] Hedley D.W., Friedlander M.L., Taylor I.W., Rugg C.A., Musgrove E.A., Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry, J Histochem Cytochem, 31, pp. 1333-1335, (1983)
12